Hyloris Celebrates Valacyclovir FDA Filing Amid Series Of Announcements

The Belgian Player Disclosed Three New Deals Through February

Following steady updates on its development of a new formulation of valacyclovir, Hyloris revealed the US FDA’s acceptance of its NDA filing while also announcing three new deals this month.

US Food and Drug Administration
(Shutterstock)

More from Value Added Medicines

More from Generics Bulletin